Cardiorentis' Heart Failure Trial Backed by $131M Investment
LONDON – The secretive backers of Cardiorentis Ltd. prefer to remain anonymous, but they obviously are expecting to see the name of the company's main asset, Ularitide, in lights, having made a €100 million (US$130.6 million) investment to put the product through a Phase III trial in treating 2,116 patients with acute heart failure.
To continue reading subscribe now to BioWorld Asia (formerly International)
Learn More about BioWorld Asia (formerly International)
Already a subscriber? Sign In or Buy now to activate your subscription
Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
Suite: 1100 | Atlanta, Georgia 30346, USA
For Sales Inquiries:
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2014 Thomson Reuters. Reproduction, reposting content is strictly prohibited.
Free Ezine
Sign up for Highlights FREE e-mail newsletter